Toshimitsu Hamasaki

Editor of Statistics in Biopharmaceutical Research | The George Washington University Biostatistics Center

[Toshimitsu Hamasaki @ToshimitsuHama1]

The 2023 Issue 3 of Statistics in Biopharmaceutical Research is out! This issue features articles from the 2021 Regulatory-Industry Statistics Workshop. https://t.co/dpHoX7DDST #ClinicalTrials #Biostatistics #DataScience

[Toshimitsu Hamasaki @ToshimitsuHama1]

A collection of articles on #estimands, design and analysis of #clinicaltrials with time-to-event outcomes #Biostatistics https://t.co/8IbpPP4Nfg

[Toshimitsu Hamasaki @ToshimitsuHama1]

We are pleased to announce the recipients of Statistics in Biopharmaceutical Research Best Papers Award 2023! Congratulations to all authors on their excellent work! #Biostatistics #clinicaltrials https://t.co/PmR7ziongu

[Toshimitsu Hamasaki @ToshimitsuHama1]

Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards | NEJM Evidence https://t.co/iRZBOrQz1L

[Frank Bretz @Frank_Bretz]

Deadline for abstracts submissions (talks and posters) at the Central European Network (CEN) conference has been extended until Sunday, 05.03.2023:
https://t.co/J6R2hYtnZo

Don't miss CEN2023 in Basel, September 3-7, 2023!
https://t.co/C55bJQE77g

@IBSstats @UniBasel

[Toshimitsu Hamasaki @ToshimitsuHama1]

All the NISS special section articles are now freely accessible for everyone until mid May. Enjoy reading the articles!

Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic https://t.co/SD4zY6YF5e

[Toshimitsu Hamasaki @ToshimitsuHama1]

The 2023 first issue of Statistics in Biopharmaceutical Research is out! The issue has a Special Section on Opportunities and Challenges in Utilizing Real-World Data for Clinical Trials and Medical Product Development. #clinicaltrials #rwd #Biostatistics https://t.co/puMLitgjEf

[Toshimitsu Hamasaki @ToshimitsuHama1]

We are seeking applications for a postdoctoral associate position to work at the George Washington University Biostatistics Center, Rockville, MD. #Biostatistics #clinicaltrials
https://t.co/xP4OlRoRmB

[Toshimitsu Hamasaki @ToshimitsuHama1]

The 2022 last issue of Statistics in Biopharmaceutical Research is out! The issue has a Special Section on "Lead and Impact: Turning Innovation into Practice: Selected Articles from RISW2020". Enjoy reading the articles!
#clinicaltrials #Biostatistics https://t.co/fDU6lsfwPo

[Toshimitsu Hamasaki @ToshimitsuHama1]

Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions #clinicaltrials #COVID #Biostatistics
https://t.co/urXIj2pHdF

[Frank Bretz @Frank_Bretz]

CEN2023 Conference: Call for session proposals now open!

The Central European Network (CEN) conference from 3-7 September, 2023, in Basel, Switzerland, is organized by the Austro-Swiss, German & Polish IBS Regions

Visit https://t.co/aDZYDujHEG for details

@IBSstats #CEN2023

[Toshimitsu Hamasaki @ToshimitsuHama1]

We are proud to announce the 2022 third issue of Statistics in Biopharmaceutical Research, an Official Publication of the American Statistical Association!

Editor’s Note https://t.co/pLDKME5vRP

[Toshimitsu Hamasaki @ToshimitsuHama1]

The 2022 Second Issue of Statistics in Biopharmaceutical Research, is out! The issue includes one discussion and eight original articles, and two letters. I hope you enjoy reading the articles! #Biostatistics #clinicaltrials @tandfSTEM
https://t.co/tmdQbHWPbl

[Toshimitsu Hamasaki @ToshimitsuHama1]

Editor’s Note- Let's think about the future direction of statistical innovation #Biostatistics #clinicaltrials https://t.co/8eXMFhUJ09

[Frank Bretz @Frank_Bretz]

Proud to see this Special Issue coming out with 10 papers on statistical challenges in clinical trials for COVID-19 treatments, vaccines, and diagnostics.
Thanks to Freda Cooner, @ToshimitsuHama1, Gene Pennello and @posch_m for the great collaboration!
https://t.co/8daj42IDgA

[Toshimitsu Hamasaki @ToshimitsuHama1]

A group of FDA statisticians evaluated the MaxCombo test using 6 cancer trials submitted to FDA. Non-proportional hazards – An evaluation of the MaxCombo Test in cancer clinical trials #clinicaltrials #biostatistics https://t.co/1tpyPtIVfc

[Toshimitsu Hamasaki @ToshimitsuHama1]

ASA President's Task Force Statement on Statistical Significance and Replicability #Statistics #biostatistics #DataScience #clinicaltrials https://t.co/kP3C9HlcHv

[Toshimitsu Hamasaki @ToshimitsuHama1]

We are pleased to announce the new practice of a biennial “Best Paper Award” for the best articles published in Statistics in Biopharmaceutical Research. We congratulate the authors for their excellent work! #BIOSTATISTICS #clinicaltrials https://t.co/1F3iW8L13S

[Toshimitsu Hamasaki @ToshimitsuHama1]

FDA CDER Statisticians' perspective on the limitations and roles of p-values in regulatory decision making @tandfonline @AmstatNews
#biostatistics #clinicaltrials
https://t.co/HXYyksxC6m